Pro DEX PDEX
- Market cap
- $184.5M
- PE
- 15.9×
- 10y median 16.5×
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 2.3×
- EV/EBIT
- 14.8×
- Revenue, 12 months
- $79.6M
- +13% on a year ago
- Net margin
- 15.1%
- Free cash flow yield
- 5.8%
Pro DEX trades at 15.9× trailing earnings, near its ten-year median. Revenue was $79.6M over the last twelve months, up 13% on a year earlier with a 15% net margin.
Charts
Financials
| Income statement | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $12.6M+12% | $14.3M+9% | $15M+41% | $14.9M+25% | $16.8M+33% | $17.4M+22% | $17.5M+16% | $18.5M+24% | $18.7M+11% | $19.9M+15% | $20.4M+17% | $20.6M+11% | |
| Cost of revenue | $9.8M+13% | $10.3M+11% | $10.9M+50% | $9.7M+18% | $11.7M+20% | $11.6M+13% | $14M+28% | $13.2M+35% | $12.9M+10% | $13.8M+19% | $13.3M−5% | $13.7M+4% |
| Gross profit | $2.8M+7% | $4M+5% | $4.1M+22% | $5.2M+41% | $5.1M+81% | $5.8M+45% | $3.5M−15% | $5.4M+4% | $5.7M+13% | $6.1M+6% | $7.1M+103% | $6.9M+28% |
| R&D | $788K+69% | $760K+7% | $836K+20% | $843K+5% | $942K+20% | $947K+25% | $905K+8% | $768K−9% | $734K−22% | $827K−13% | $1M+12% | $1.2M+58% |
| SG&A | $1.2M+21% | $1M−0% | $902K−14% | $1.3M+27% | $1.4M+16% | $1.2M+18% | $1.2M+38% | $1.5M+15% | $1.8M+22% | $2.2M+83% | $2.5M+105% | $2.1M+43% |
| $777K−32% | $2.2M+7% | $2.4M+46% | $3M+64% | $2.7M+247% | $3.6M+65% | $1.3M−43% | $3.1M+3% | $3.3M+21% | $3.1M−15% | $3.5M+163% | $3.5M+13% | |
| Interest expense | $139K+9% | $138K+5% | $149K+4% | $152K+14% | $204K+47% | $246K+78% | $227K+52% | $200K+32% | $141K−31% | $201K−18% | $270K+19% | $260K+30% |
| Pre-tax income | $620K−84% | $913K−58% | $1.9M−4% | $3.3M | $2.6M+317% | $4.6M+399% | $1.6M−17% | $6.2M+88% | $2.9M+13% | $5.3M+17% | $3.5M+121% | $3.4M−46% |
| $120K−88% | $258K−55% | $343K−33% | $853K | $546K+355% | $1.3M+396% | $402K+17% | $1.5M+81% | $741K+36% | $1.4M+10% | $668K+66% | $331K−79% | |
| Net income | $500K−82% | $655K−60% | $1.6M+6% | $2.5M | $2M+308% | $3.3M+400% | $1.2M−25% | $4.7M+90% | $2.2M+7% | $3.9M+20% | $2.9M+139% | $3M−35% |
| $0.14−81% | $0.19−58% | $0.46+10% | $0.75 | $0.61+336% | $0.98+416% | $0.36−22% | $1.40+87% | $0.66+8% | $1.20+22% | $0.85+136% | $0.92−34% | |
| 3.6M−1% | 3.5M−3% | 3.5M−3% | 3.3M−7% | 3.3M−8% | 3.3M−5% | 3.3M−4% | 3.3M+1% | 3.3M−1% | 3.3M−2% | 3.4M+1% | 3.3M−1% |
EPS, diluted: 20 periods, Q4 FY11 to Q4 FY26: quarter's net income to common over its shares, to the cent.
Diluted shares: 14 periods, Q4 FY11 to Q4 FY26: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY12 and Q4 FY13: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Instruments & Supplies nearest Pro DEX's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| PDEXPro DEX | $184.5M | 15.9× | 16.5× | 2.3× | +13% | 15.1% | |
| UTMDUtah Medical Products | $224.6M | 21.5× | 20.9× | 6.2× | −7% | 29.0% | |
| INFUInfuSystem | $275.7M | 33.8× | 43.5× | 1.9× | +2% | 6.0% | |
| EMBCEmbecta | $350.7M | 4.2× | 11.6× | 0.3× | −8% | 8.6% | |
| KEQUKewaunee Scientific | $96.7M | 12.1× | 13.6× | 0.3× | +5% | 3.0% | |
| TCMDTactile Systems Technology | $518.1M | 21.2× | 62.3× | 1.5× | +17% | 7.1% | |
| APTAlpha Pro Tech | $56.3M | 13.5× | 14.8× | 0.9× | +6% | 6.8% | |
| MOVMovado | $710.9M | 17.7× | 13.4× | 1.0× | +5% | 6.0% | |
| NEPHNephros | $35.2M | 20.3× | 28.3× | 1.7× | +24% | 8.4% | |
| IRMDIradimed | $1B | 42.5× | 41.5× | 11.4× | +11% | 26.8% | |
| IARTIntegra Lifesciences | $1.1B | 80.1× | 46.3× | 0.6× | +1% | 0.8% | |
| Peer median | $313.2M | 20.7× | 24.6× | 1.3× | +5% | 6.9% |
More on Pro DEX
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #10of 80Medical instruments and supplies stocks with the highest profit margins
- #7of 35Medical instruments and supplies stocks with the lowest PE ratio
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .